Reference:
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K. L., Robb, M. L., Treanor, J., Barouch, D. H., Stoddard, J., Ryser, M. F., Marovich, M. A., Neuzil, K. M., Corey, L., Cauwenberghs, N., Tanner, T., Hardt, K., Ruiz-Guiñazú, J., Le Gars, M., Schuitemaker, H., Van Hoof, J., Struyf, F., & Douoguih, M. (2021). Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine, 384(23), 2187-201. https://doi.org/10.1056/NEJMoa2101544
Summary:
The Ad26.COV2.S vaccine, a single-dose, replication-incompetent adenovirus-based vaccine, showed 66.9% efficacy against moderate to severe Covid-19 in a phase 3 trial involving 39,321 participants. Efficacy was higher against severe cases (76.7%) and maintained in regions with variants like the 20H/501Y.V2. Reactogenicity was mild to moderate, with a balance of serious adverse events between vaccine and placebo groups. The study highlights the vaccine’s potential to reduce severe disease, hospitalisation, and death, with a safety profile comparable to other vaccines.